Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma

The clinical significance of circulating cell-free DNA (cfDNA) integrity as diagnostic and surveillance biomarker in hepatocellular carcinoma (HCC) was investigated and compared to that of alpha fetoprotein (AFP). Liver cancer patients had lower cfDNA integrity than those with benign diseases (P = 0...

Full description

Bibliographic Details
Main Authors:	Huang, Ao, Zhang, Xin, Zhou, Shao-Lai, Cao, Ya, Huang, Xiao-Wu, Fan, Jia, Yang, Xin-Rong, Zhou, Jian
Format:	Online
Language:	English
Published:	Ivyspring International Publisher 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039362/

id	pubmed-5039362
recordtype	oai_dc
spelling	pubmed-50393622016-10-03 Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma Huang, Ao Zhang, Xin Zhou, Shao-Lai Cao, Ya Huang, Xiao-Wu Fan, Jia Yang, Xin-Rong Zhou, Jian Research Paper The clinical significance of circulating cell-free DNA (cfDNA) integrity as diagnostic and surveillance biomarker in hepatocellular carcinoma (HCC) was investigated and compared to that of alpha fetoprotein (AFP). Liver cancer patients had lower cfDNA integrity than those with benign diseases (P = 0.0167) and healthy individuals (P = 0.0025). Patients with HCC and non-HCC liver cancers (P = 0.7356), and patients with benign diseases and healthy individuals (P = 0.9138) had comparable cfDNA integrity respectively. cfDNA integrity increased after hepatectomy in cancer patients (P = 0.0003). The AUCs for detecting HCC by cfDNA integrity and AFP were 0.705 (P = 0.005) and 0.605 (P = 0.156), respectively. We found cfDNA integrity decreased in HCC patients and has the potential as promising biomarker for HCC diagnosis and treatment surveillance. Ivyspring International Publisher 2016-08-12 /pmc/articles/PMC5039362/ /pubmed/27698918 http://dx.doi.org/10.7150/jca.15618 Text en © Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Huang, Ao Zhang, Xin Zhou, Shao-Lai Cao, Ya Huang, Xiao-Wu Fan, Jia Yang, Xin-Rong Zhou, Jian
spellingShingle	Huang, Ao Zhang, Xin Zhou, Shao-Lai Cao, Ya Huang, Xiao-Wu Fan, Jia Yang, Xin-Rong Zhou, Jian Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma
author_facet	Huang, Ao Zhang, Xin Zhou, Shao-Lai Cao, Ya Huang, Xiao-Wu Fan, Jia Yang, Xin-Rong Zhou, Jian
author_sort	Huang, Ao
title	Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma
title_short	Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma
title_full	Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma
title_fullStr	Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma
title_full_unstemmed	Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma
title_sort	plasma circulating cell-free dna integrity as a promising biomarker for diagnosis and surveillance in patients with hepatocellular carcinoma
description	The clinical significance of circulating cell-free DNA (cfDNA) integrity as diagnostic and surveillance biomarker in hepatocellular carcinoma (HCC) was investigated and compared to that of alpha fetoprotein (AFP). Liver cancer patients had lower cfDNA integrity than those with benign diseases (P = 0.0167) and healthy individuals (P = 0.0025). Patients with HCC and non-HCC liver cancers (P = 0.7356), and patients with benign diseases and healthy individuals (P = 0.9138) had comparable cfDNA integrity respectively. cfDNA integrity increased after hepatectomy in cancer patients (P = 0.0003). The AUCs for detecting HCC by cfDNA integrity and AFP were 0.705 (P = 0.005) and 0.605 (P = 0.156), respectively. We found cfDNA integrity decreased in HCC patients and has the potential as promising biomarker for HCC diagnosis and treatment surveillance.
publisher	Ivyspring International Publisher
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039362/
_version_	1613663239947681792

Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma

Similar Items